Drugs / BNT116
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05142189 | Jun 2022 → Feb 2030 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05557591 | Apr 2023 → Jan 2028 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-24 | BioNTech SE | Results BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 biontech.com ↗
The preliminary data showed anti-tumor activity, consistent immune response induction, and a manageable safety profile. |
| 2024-03-11 | BioNTech SE | Results BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 biontech.com ↗
The data show antitumor activity, consistent induction of immune responses in heavily pre-treated patients with advanced NSCLC, and a manageable safety profile. |
| 2023-10-31 | BioNTech SE | Results BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting biontech.com ↗
The data show encouraging initial clinical activity in heavily pre-treated patients with advanced NSCLC and a tolerable safety profile. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142189 ↗ |
| Modality | Vaccine | “cancer vaccine BNT116” NCT05557591 ↗ |
| Route | Intravenous | “Intravenous injection” NCT05142189 ↗ |